Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intrapulmonary concentrations of pyrazinamide.

J E Conte1, J A Golden, S Duncan

  • 1Infectious Diseases Research Laboratory, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California 94143-0208, USA. JCONTE@AIDS.UCSF.EDU

Antimicrobial Agents and Chemotherapy
|May 29, 1999
PubMed
Summary

This study found that pyrazinamide concentrations in plasma were similar between normal volunteers and individuals with AIDS. However, intrapulmonary concentrations in epithelial lining fluid and alveolar cells were slightly lower in the AIDS group, though not significantly.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'Handing down of beautiful knowledge': Yarning with workers about feeding practices and mealtimes in Australian First Nations families.

Appetite·2024
Same author

Correction: Validation of actigraphy sleep metrics in children aged 8 to 16 years: considerations for device type, placement and algorithms.

The international journal of behavioral nutrition and physical activity·2024
Same author

Validation of actigraphy sleep metrics in children aged 8 to 16 years: considerations for device type, placement and algorithms.

The international journal of behavioral nutrition and physical activity·2024
Same author

Multisensory perception constrains the formation of object categories: a review of evidence from sensory-driven and predictive processes on categorical decisions.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2023
Same author

Health-promoting and health-constraining environmental features and physical activity and sedentary behaviour in adolescence: a geospatial cross-sectional study.

Health & place·2022
Same author

Efficient quantitative assessment of robot swarms: coverage and targeting Lévy strategies.

Bioinspiration & biomimetics·2022

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Pyrazinamide is a crucial first-line drug for tuberculosis treatment.
  • Understanding its pharmacokinetics in different patient populations is essential for optimizing therapy.
  • Acquired Immunodeficiency Syndrome (AIDS) can alter drug metabolism and distribution.

Purpose of the Study:

  • To compare steady-state plasma and intrapulmonary concentrations of pyrazinamide in healthy individuals and patients with AIDS.
  • To investigate the influence of AIDS and gender on pyrazinamide distribution.
  • To assess the intrapulmonary drug levels relative to the minimum inhibitory concentration (MIC) for Mycobacterium tuberculosis.

Main Methods:

  • Oral administration of 1 g pyrazinamide daily for 5 days to 40 adult volunteers (20 healthy, 20 with AIDS).

Related Experiment Videos

  • Blood, epithelial lining fluid (ELF), and alveolar cells (AC) were collected at specific time points post-dose.
  • Pyrazinamide concentrations were quantified using high-performance liquid chromatography (HPLC).

    • Main Results:

    • Plasma concentrations of pyrazinamide showed no significant difference between healthy subjects and those with AIDS, or between genders.
    • Intrapulmonary concentrations in ELF and AC were numerically lower in subjects with AIDS but did not reach statistical significance.
    • ELF pyrazinamide concentrations were substantially high (431 ± 220 μg/mL), exceeding the MIC for susceptible M. tuberculosis strains.

    Conclusions:

    • AIDS and gender do not significantly impact plasma pyrazinamide levels.
    • While intrapulmonary concentrations may be slightly reduced in AIDS patients, they remain high.
    • High ELF concentrations of pyrazinamide likely contribute to its efficacy in treating pulmonary tuberculosis.